Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity Deficit - USD ($) $ in Thousands	Total	Convertible Preferred Stock	Pfizer License Agreement Convertible Preferred Stock	Common Stock	Additional paid-in capital	Accumulated deficit
Beginning balance at Dec. 31, 2020		$ 21,942
Beginning Balance, Shares at Dec. 31, 2020		22,724,925
Beginning balance at Dec. 31, 2020	$ (15,645)			$ 1	$ 97	$ (15,743)
Beginning Balance, Shares at Dec. 31, 2020				1,289,342
Issuance of Series B convertible preferred stock		$ 152,081	$ 20,000
Issuance of Series B convertible preferred stock, Shares		92,660,103	12,152,145
Vesting of restricted common stock	3				3
Vesting of restricted common stock (Shares)				123,085
Stock-based compensation	2,450				2,450
Net loss	(36,825)					(36,825)
Ending balance at Mar. 31, 2021		$ 194,023
Ending balance (in shares) at Mar. 31, 2021		127,537,173
Ending balance at Mar. 31, 2021	(50,017)			$ 1	2,550	(52,568)
Ending balance (in shares) at Mar. 31, 2021				1,412,427
Beginning balance at Dec. 31, 2021	261,313			$ 32	352,999	(91,718)
Beginning Balance, Shares at Dec. 31, 2021				32,222,881
Stock options exercised	$ 176				176
Stock options exercised (Shares)	51,118			51,118
Vesting of restricted common stock	$ 1				1
Vesting of restricted common stock (Shares)				100,908
Stock-based compensation	3,404				3,404
Net loss	(31,380)					(31,380)
Ending balance at Mar. 31, 2022	$ 233,514			$ 32	$ 356,580	$ (123,098)
Ending balance (in shares) at Mar. 31, 2022				32,374,907